EDI 200

Drug Profile

EDI 200

Alternative Names: APO-200; EDI200; Fc EDA1; Fc:EDA-A1 fusion protein; Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein; Hypohidrotic ectodermal dysplasia therapy - Edimer; Recombinant ectodysplasin A1; Recombinant EDA1; XLHED therapy - Edimer

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apoxis
  • Developer Edimer Pharmaceuticals
  • Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ectodermal dysplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ectodermal dysplasia

Most Recent Events

  • 01 Dec 2015 Edimer Pharmaceuticals completes a phase II trial for Ectodermal dysplasia (in neonates, treatment-naive) in USA, United Kingdom, France, Germany, and Italy (NCT01775462)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
  • 24 Jun 2014 Edimer Pharmaceuticals enters into collaboration with InformedDNA for the development of EDI 200
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top